BMJ Open:COPD患者预后相关因素

2016-01-03 Seven L 译 MedSci原创

研究组进行了一项研究,探究高碳酸血症能否预测慢性阻塞性肺疾病(COPD)的预后。该前瞻性队列研究共纳入了275名40-85岁稳定期COPD患者(不包含影响 PaCO2 相关并发症的患者如阻塞性睡眠呼吸暂停症、肥胖引起的肺换气不足或神经肌肉疾病),通过血气分析检测血碳酸情况,比较了不同血碳酸含量COPD患者的生存,其中血碳酸含量正常的有98人,高于正常的慢性高碳酸血症有177人。研究数据显示,血碳酸

研究组进行了一项研究,探究高碳酸血症能否预测慢性阻塞性肺疾病(COPD)的预后。该前瞻性队列研究共纳入了275名40-85岁的稳定期COPD患者(不包含影响PaCO2 相关并发症的患者,如阻塞性睡眠呼吸暂停症、肥胖引起的肺换气不足或神经肌肉疾病),通过血气分析检测血碳酸情况,比较了不同血碳酸含量COPD患者的生存,其中血碳酸含量正常的有98人,高于正常的慢性高碳酸血症有177人。

研究数据显示,血碳酸含量组与慢性高碳酸血症组相比,中位数生存时间更长(6.5 vs 5.0 年, p=0.016)。多因素COX回顾分析显示年龄(HR=1.043, 95% CI 1.012 to 1.076)、查尔森合并症指数(HR=1.172, 95% CI 1.067 to 1.288)、药物使用HR=0.565, 95% CI 0.379 to 0.842)、BMI(HR=0.922, 95% CI 0.883 to 0.963)、PaCO2(HR=1.026, 95% CI 1.011 to 1.042)、肺心病 (HR=2.164, 95% CI 1.557 to 3.006)、无创正压通气(NPPV) (HR=0.615, 95% CI 0.429 to 0.881)以及FEV1%(HR=0.979, 95% CI 0.967 to 0.991)是死亡率相关的独立危险因素。

研究结果表明,随年龄、查尔森合并症指数、肺心病的增加以及FEV1%、药物使用、BMI、无创正压通气的减少均会导致COPD患者预后更差。

原始出处:

Yang H, Xiang P, Zhang E,et al.Is hypercapnia associated with poor prognosis in chronic obstructive pulmonary disease? A long-term follow-up cohort study.BMJ Open. 2015 Dec 15;5(12):e008909.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1725993, encodeId=43c61e2599374, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 12 05:46:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691866, encodeId=276f169186654, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 10 14:46:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847840, encodeId=9366184e840d9, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon May 16 14:46:00 CST 2016, time=2016-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64432, encodeId=a051644320a, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Tue Feb 16 10:06:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457449, encodeId=a7ee145e4495e, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488782, encodeId=aa951488e827e, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51696, encodeId=5c7f516968d, content=有临床价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51695, encodeId=933251695fc, content=还是很有用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:54:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
    2016-06-12 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1725993, encodeId=43c61e2599374, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 12 05:46:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691866, encodeId=276f169186654, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 10 14:46:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847840, encodeId=9366184e840d9, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon May 16 14:46:00 CST 2016, time=2016-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64432, encodeId=a051644320a, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Tue Feb 16 10:06:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457449, encodeId=a7ee145e4495e, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488782, encodeId=aa951488e827e, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51696, encodeId=5c7f516968d, content=有临床价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51695, encodeId=933251695fc, content=还是很有用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:54:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1725993, encodeId=43c61e2599374, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 12 05:46:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691866, encodeId=276f169186654, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 10 14:46:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847840, encodeId=9366184e840d9, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon May 16 14:46:00 CST 2016, time=2016-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64432, encodeId=a051644320a, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Tue Feb 16 10:06:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457449, encodeId=a7ee145e4495e, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488782, encodeId=aa951488e827e, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51696, encodeId=5c7f516968d, content=有临床价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51695, encodeId=933251695fc, content=还是很有用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:54:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
    2016-05-16 gaoxiaoe
  4. [GetPortalCommentsPageByObjectIdResponse(id=1725993, encodeId=43c61e2599374, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 12 05:46:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691866, encodeId=276f169186654, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 10 14:46:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847840, encodeId=9366184e840d9, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon May 16 14:46:00 CST 2016, time=2016-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64432, encodeId=a051644320a, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Tue Feb 16 10:06:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457449, encodeId=a7ee145e4495e, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488782, encodeId=aa951488e827e, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51696, encodeId=5c7f516968d, content=有临床价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51695, encodeId=933251695fc, content=还是很有用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:54:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
    2016-02-16 ssummer

    赞!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1725993, encodeId=43c61e2599374, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 12 05:46:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691866, encodeId=276f169186654, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 10 14:46:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847840, encodeId=9366184e840d9, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon May 16 14:46:00 CST 2016, time=2016-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64432, encodeId=a051644320a, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Tue Feb 16 10:06:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457449, encodeId=a7ee145e4495e, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488782, encodeId=aa951488e827e, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51696, encodeId=5c7f516968d, content=有临床价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51695, encodeId=933251695fc, content=还是很有用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:54:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1725993, encodeId=43c61e2599374, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 12 05:46:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691866, encodeId=276f169186654, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 10 14:46:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847840, encodeId=9366184e840d9, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon May 16 14:46:00 CST 2016, time=2016-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64432, encodeId=a051644320a, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Tue Feb 16 10:06:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457449, encodeId=a7ee145e4495e, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488782, encodeId=aa951488e827e, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51696, encodeId=5c7f516968d, content=有临床价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51695, encodeId=933251695fc, content=还是很有用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:54:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
    2016-01-05 gous
  7. [GetPortalCommentsPageByObjectIdResponse(id=1725993, encodeId=43c61e2599374, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 12 05:46:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691866, encodeId=276f169186654, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 10 14:46:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847840, encodeId=9366184e840d9, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon May 16 14:46:00 CST 2016, time=2016-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64432, encodeId=a051644320a, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Tue Feb 16 10:06:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457449, encodeId=a7ee145e4495e, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488782, encodeId=aa951488e827e, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51696, encodeId=5c7f516968d, content=有临床价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51695, encodeId=933251695fc, content=还是很有用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:54:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
    2016-01-04 lu2996

    有临床价值

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1725993, encodeId=43c61e2599374, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jun 12 05:46:00 CST 2016, time=2016-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691866, encodeId=276f169186654, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 10 14:46:00 CST 2016, time=2016-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847840, encodeId=9366184e840d9, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon May 16 14:46:00 CST 2016, time=2016-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=64432, encodeId=a051644320a, content=赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLRP2D8sTDxkrGNjMqwyLUGd9Wbt6L0Yw9goia4ibPGLEx48lF9kvw86FKicbdWemTqujrf6K5WPIic8g/132, createdBy=69a11636814, createdName=ssummer, createdTime=Tue Feb 16 10:06:00 CST 2016, time=2016-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1457449, encodeId=a7ee145e4495e, content=<a href='/topic/show?id=4159e25296d' target=_blank style='color:#2F92EE;'>#相关因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72529, encryptionId=4159e25296d, topicName=相关因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=19655942413, createdName=zzc2213, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488782, encodeId=aa951488e827e, content=<a href='/topic/show?id=69675090ca' target=_blank style='color:#2F92EE;'>#COPD患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5090, encryptionId=69675090ca, topicName=COPD患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=852e8475198, createdName=gous, createdTime=Tue Jan 05 06:46:00 CST 2016, time=2016-01-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51696, encodeId=5c7f516968d, content=有临床价值, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:55:00 CST 2016, time=2016-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51695, encodeId=933251695fc, content=还是很有用的, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c1b91651063, createdName=lu2996, createdTime=Mon Jan 04 12:54:00 CST 2016, time=2016-01-04, status=1, ipAttribution=)]
    2016-01-04 lu2996

    还是很有用的

    0

相关资讯

Resp Med:音乐疗法对慢性病患者大有裨益!

在美国COPD是第四大死因,表现为呼吸困难、咳嗽起床、胸痛等。一项对68名包括COPD在内的慢性呼吸道疾病患者的研究表明,传统治疗联合音乐疗法(与仅仅传统治疗相比)可显著改善患者症状、心理健康以及生活质量。参与者在研究的6周时间内,随机参与到不同音乐疗法组,包括现场音乐、可视化音乐、风乐器演奏和演唱(合并呼吸控制技术)。音乐疗法结合了病人喜欢的音乐,鼓励其自我表达,增加参与治疗的机会,以应对慢性疾

CHEST:COPD的加重与透明质酸的炎性降解相关

慢性阻塞性肺病(COPD)的特征是慢性气道炎症及重塑,与细胞外基质(ECM)的严重变形。透明质酸(HA)是一种丰富的细胞外基质分子,在肺中具有不同的生物功能,这取决于其分子量(MW)。高MW的HA具有抗炎和免疫抑制作用,而MW的HA可促发炎症。在这项研究中,研究人员调查了是否COPD急性加重期(AECOPDs)(影响患者的生活和生存生存质量)和BAL中的HA改变有关,研究人员使用了COPD稳定期患

Thorax:长效β受体阻滞剂与长效毒蕈碱受体拮抗剂联合治疗COPD的疗效与安全分析

背景:长效β受体激动剂和长效毒蕈碱受体拮抗剂(LABA / LAMA)的联合在治疗病情稳定的慢性阻塞性肺疾病患者中的重要性是不明确。本次研究的目的是系统性回顾LABA/LAMA联合的疗效与安全性。方法:在几个数据库与大量的网址中检索相关的临床试验。采用随机对照实验,为期至少12周,分为LABA/LAMA联合治疗组,与安慰剂/单一疗法组。所有数据使用网络以及传统直接的比较荟萃分析。结果:纳入23个研

Chest:COPD患者存在明显的嗜酸细胞炎症

慢性阻塞性肺疾病(COPD)是美国第三大死亡因素。FeNO水平可用于标记嗜酸细胞炎症。研究人员分析评估COPD受试者人群的FeNO水平。研究人员分析了来自NHANES患者数据,时间为2007年到2010年期间。用吸入支气管扩张剂后FEV1/ FVC< 0.70以及长期存在的持续性气流受限来定义COPD病例。因食用食物,吸入糖皮质激素,或者既往呼吸系统疾病病史的缺乏两次可重复性FeNO水平的病

Lancet Respir Med:COPD患者可尝试使用神经肌肉电刺激疗法改善症状

骨骼肌功能障碍和运动耐受不良是严重的慢性阻塞性肺疾病(COPD)常见症状。研究人员评估了神经肌肉电刺激(NMES)作为一个以家庭为基础的运动疗法的有效性。 在这项双盲,安慰剂对照试验中,研究人员在三个英国国家健康服务的网站进行,随机分配(1:1)成人慢性阻塞性肺病,1秒(FEV1)用力呼气量低于预测的50%,并导致呼吸困难(医学研究理事会的呼吸困难量表评分≥4)的患者接受积极的或安慰剂N

CHEST:COPD患者停止使用吸入性糖皮质激素可减少肺炎发生

广泛使用吸入性糖皮质激素(ICS)对慢性阻塞性肺病(COPD)的治疗一直受到质疑。最近的一些对于COPD患者停止服用ICS的一些研究发现,与长效支气管扩张剂相比,很少或没有不良后果。然而,ICS停药是否会降低这些药物增加的肺炎的风险目前还不清楚。研究人员使用魁北克健康保险数据库,形成了一个新的使用人群队列,这些患者为在1990年-2005年使用ICS治疗的COPD患者,随后到2007年,或直至发生